TELA Bio director buys 75,000 shares in market

TELA Bio, Inc. (TELA) director Joseph H. Capper reported open-market purchases of the company’s common stock on two consecutive days in September 2026.

Rhea-AI Filing Summary

TELA Bio, Inc. (TELA) director Joseph H. Capper reported open-market purchases of the company’s common stock on two consecutive days in September 2026. He bought 50,000 shares on September 16, 2026 at a weighted average price of $1.1653 per share and 25,000 shares on September 17, 2026 at a weighted average price of $1.2212 per share. The purchases were executed across multiple trades, with prices on September 16 ranging from $1.14–$1.20 and on September 17 from $1.19–$1.25 per share, and no Rule 10b5-1 trading plan is reported.

Insider Trade Summary

Net Buyer: 75,000 shares

Net Buy 2 txns

Insider Capper Joseph H

Role Director

Bought 75,000 shs ($89K)

Type	Security	Shares	Price	Value
Purchase	Common Stock F2	25,000	$1.2212	$31K
Purchase	Common Stock F1	50,000	$1.1653	$58K

Holdings After Transaction: Common Stock — 179,827 shares (Direct)

Footnotes (2)

1. F1. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.14 to $1.20. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
2. F2. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.19 to $1.25. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Key Figures

Shares purchased September 16, 2026: 50,000 shares Weighted average price September 16, 2026: $1.1653 per share Shares purchased September 17, 2026: 25,000 shares +3 more

6 metrics

Shares purchased September 16, 2026 50,000 shares Open-market purchase of TELA Bio common stock by a director

Weighted average price September 16, 2026 $1.1653 per share Shares purchased in multiple trades from $1.14–$1.20

Shares purchased September 17, 2026 25,000 shares Second-day open-market purchase of TELA Bio common stock

Weighted average price September 17, 2026 $1.2212 per share Shares purchased in multiple trades from $1.19–$1.25

Total shares purchased over both days 75,000 shares Combined insider buying on September 16–17, 2026

Rule 10b5-1 status No trading plan reported Document-level 10b5-1 checkbox is not selected

Key Terms

weighted average price, open market or private transaction, Rule 10b5-1

3 terms

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open market or private transaction financial

"Purchase in open market or private transaction"

Rule 10b5-1 regulatory

"No Rule 10b5-1 trading plan is reported for these transactions"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did TELA (TELA) report in this Form 4?

Director Joseph H. Capper reported two open-market purchases of TELA Bio common stock, totaling 75,000 shares, on September 16 and 17, 2026, at weighted average prices of $1.1653$1.2212 per share, respectively.

How many TELA (TELA) shares did the director buy on each date?

On September 16, 2026, the director purchased 50,000 shares of TELA Bio common stock. On September 17, 2026, he purchased an additional 25,000 shares, for a combined total of 75,000 shares acquired over the two days.

What prices were paid for the TELA (TELA) shares in these insider purchases?

The weighted average price was $1.1653 per share for the 50,000 shares bought on September 16, 2026, with trade prices from $1.14–$1.20. On September 17, 2026, the 25,000 shares had a weighted average price of $1.2212, with trades from $1.19–$1.25.

Were the TELA (TELA) insider purchases made under a Rule 10b5-1 trading plan?

No. The filing indicates no Rule 10b5-1 trading plan; the document-level checkbox for trades under such a plan is not selected, and the footnotes describe only weighted average pricing across multiple trades.

Is the TELA (TELA) director’s ownership direct or indirect for these purchased shares?

The Form 4 reports the acquired TELA Bio common shares as directly owned by the reporting person, with the ownership type marked as direct and no intermediary entity or special ownership nature disclosed in the footnotes.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/18/2026 - 04:30 PM Accepted by SEC EDGAR 09/18/2026 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Capper Joseph H

(Last) (First) (Middle)

C/O TELA BIO, INC.

1 GREAT VALLEY PARKWAY, SUITE 24

(Street)

MALVERN PENNSYLVANIA 19355

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
TELA Bio, Inc. [ TELA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/16/2026		P		50,000	A	$1.1653(1)	154,827	D
Common Stock	09/17/2026		P		25,000	A	$1.2212(2)	179,827	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.14 to $1.20. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

2. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.19 to $1.25. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

	/s/ Megan Smeykal, Attorney-in-Fact	09/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)